Time domain

Texas Mineral Resources Completes Phase 3 Geophysical Surveying in New Mexico’s Blackhawk Silver Mining District

Retrieved on: 
Thursday, March 9, 2023
Diamond, Nature, Vein, Metal, Anomaly, OTCQB, TDEM, Water, Silver, Time domain, Probability, Graphite, TMRC, Round Top, Mining, Rare-earth element

Blackhawk silver project complements the continued successful development of the Round Top heavy-rare earth and critical mineral project in Texas.

Key Points: 
  • Blackhawk silver project complements the continued successful development of the Round Top heavy-rare earth and critical mineral project in Texas.
  • Texas Mineral Resources Corp. (TMRC), is pleased to announce that it has conducted a 3rd Phase of electro-magnetic surveying based on continued analysis of the highly encouraging Phase 2 Time Domain Electro-Magnetic (TDEM) survey of high-grade silver veins in the Black Hawk District, Grant County, New Mexico.
  • This 3rd Phase survey is focused on the area of the highest population of significant anomalies detected by Phase 2.
  • “Additionally, we are very pleased with the development of the Round Top heavy-rare earth and critical mineral project in Texas.

Quantum-Si Announces Commercial Availability of PlatinumTM, the World’s First Next-Generation Single-Molecule Protein Sequencing Platform

Retrieved on: 
Tuesday, December 20, 2022
Research, Technology, Semiconductor, Genetics, Health Technology, Biotechnology, Pharmaceutical, Health, Science, Other Science, Humanitarian use licenses, Protein sequencing, Merck Millipore, Organic acid, Sartorius, Drug discovery, National Medal, National Medal of Technology and Innovation, CCO, Partnership, Innovation, Biomedical Research, Growth, COVID-19, Marketing, Proteomics, Time domain, Proteome, DNA, Multimedia, Movement, Risk, Doctor of Philosophy, Microscope, Management, Fine chemical, Risk management, Illumina, Fortis, Platinum

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the commercial availability of Platinum™, the world’s first next-generation single-molecule protein sequencing platform.

Key Points: 
  • Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the commercial availability of Platinum™, the world’s first next-generation single-molecule protein sequencing platform.
  • With many on the leadership team having played an active role in the advent of next-generation sequencing technology, Quantum-Si is well positioned to disrupt the current state of protein sequencing.
  • “Next-generation protein sequencing represents the vanguard of new therapeutic discovery, however, no other company has met the promise of delivering an accessible single-molecule protein sequencing platform – until today,” said Jeff Hawkins, CEO of Quantum-Si.
  • In contrast, Quantum-Si’s next-generation sequencing system leverages Time Domain Sequencing™ technology which alleviates this hurdle by monitoring for amino-acid specific patterns in fluorescent probe behavior.

Analysis of Geophysical Surveying in New Mexico's Blackhawk Silver Mining District Exceeds Expectations

Retrieved on: 
Wednesday, November 30, 2022
Radium, Round Top, Anomaly, Round Top Mountain, CAPEX, TMRC, Disclosure, Economics, Time domain, Acquisition, Port Radium, Arsenic, NWT, South Tyrol Option Agreement, Graphite, Accident, Uranium, Central City/Black Hawk Historic District, Annual report, Risk, TDEM, Map, OTCQB, Water, Vein, Outline, Nickel, Form 10-K, Silver, Czech Republic, Sand, Mining, Risk management, Alhambra, Cobalt

Within these mineralized lenses, silver grades as high as 20% have been reported in the past.

Key Points: 
  • Within these mineralized lenses, silver grades as high as 20% have been reported in the past.
  • The Black Hawk District was active in the 1884-1894 period during which time the Black Hawk and the Alhambra mines accounted for most of the production.
  • to assess the Black Hawk District using its Time Domain Electro Magnetic (TDEM) surveying process.
  • Assuming historical grade recoveries and successfully accessing the veins identified, the risk/reward potential of the Blackhawk district is quite favorable.

Quantum-Si’s Next-Generation Single-Molecule Protein Sequencing Technology Published in Science, Signaling New Era of Life Science and Biomedical Research

Retrieved on: 
Thursday, October 13, 2022
Science, Biotechnology, Research, General Health, Health, Technology, Genetics, Semiconductor, Proteomics, Disease, SEC, Nasdaq, Technology, Growth, Diagnosis, Organic acid, Paper, Nobel Prize, Genomics, National Medal of Technology and Innovation, Research, Cell, Enzyme, Partnership, Finite-state machine, Private Securities Litigation Reform Act, Company, Drug discovery, Marketing, Health, Kinetics, American Association, Association, National Medal, Innovation, American Association for Clinical Chemistry, Protein, DNA, Cataloging, Time domain, Peptide, Biomedical Research, COVID-19, Research Institute for Advanced Computer Science, Risk, Fine chemical, Microscope, Science, Aminopeptidase

Oct. 13, 2022-- Quantum-Si Incorporated (Nasdaq: QSI) (Quantum-Si, QSI or the Company), a life sciences company commercializing the first next-generation single-molecule protein sequencing platform, today announced that Science , the peer-reviewed academic journal of the American Association for the Advancement of Science, published new research showcasing how single-molecule protein sequencing via semiconductor chip and Time Domain Sequencing technologies will transform life science and biomedical research.

Key Points: 
  • Oct. 13, 2022-- Quantum-Si Incorporated (Nasdaq: QSI) (Quantum-Si, QSI or the Company), a life sciences company commercializing the first next-generation single-molecule protein sequencing platform, today announced that Science , the peer-reviewed academic journal of the American Association for the Advancement of Science, published new research showcasing how single-molecule protein sequencing via semiconductor chip and Time Domain Sequencing technologies will transform life science and biomedical research.
  • I am proud and excited to share the first next-generation single-molecule protein sequencing technology with the world, said Dr. Rothberg, senior author of the paper.
  • This approach eliminates roadblocks of complex chemistry and large, expensive equipment facing other technologies, while providing the sensitivity, scalability, and accessibility needed to accelerate biomedical research.
  • More information, including a copy of the paper, can be found online at the Science press package at https://www.eurekalert.org/press/scipak/ .

Quantum-Si Highlights Technology Advancements at the VIB Next-Generation Protein Analysis and Detection Conference

Retrieved on: 
Wednesday, June 1, 2022
Oncology, Health, Medical Devices, Research, Science, Pharmaceutical, Biotechnology, Photon, Cardiology, Biomarker, Amino acid, Nasdaq, Company, Research, Proteome, Marketing, Conference, Partnership, Time domain, Protein engineering, Investor, Humanitarian use licenses, Risk, Proteomics, Growth, Organic acid, Neurology, Private Securities Litigation Reform Act, Technology, DNA, COVID-19, SEC, Drug discovery, Protein, Microscope, Fine chemical

1, 2022 -- Quantum-Si Incorporated (Nasdaq: QSI) (Quantum-Si, QSI or the Company), a life sciences company commercializing single molecule protein sequencing, announced that Brian Reed, Ph.D., Head of Research at Quantum-Si, presented an update on the Companys technology advancements at the Next-Generation Protein Analysis and Detection Conference, a VIB Tools & Technologies conference, in Ghent, Belgium.

Key Points: 
  • 1, 2022 -- Quantum-Si Incorporated (Nasdaq: QSI) (Quantum-Si, QSI or the Company), a life sciences company commercializing single molecule protein sequencing, announced that Brian Reed, Ph.D., Head of Research at Quantum-Si, presented an update on the Companys technology advancements at the Next-Generation Protein Analysis and Detection Conference, a VIB Tools & Technologies conference, in Ghent, Belgium.
  • Dr. Reed discussed Quantum-Sis research and development progress, including the expansion of the technology to interrogate more of the human proteome and its estimated 1,000,000+ proteoforms.
  • This is essential for researchers to gain insights into how protein changes impact disease states.
  • To learn more about Quantum-Sis technology, download the Companys latest whitepaper, titled Digitizing Protein Sequencing: Detecting Individual Amino Acids through Real-Time Photon Emission, here .

Optical Coherence Tomography Market Worth $5.28 Billion by 2030: Grand View Research, Inc.

Retrieved on: 
Monday, April 25, 2022
COVID-19, Macular degeneration, Adoption, OCT, Ophthalmology, Revenue, Time domain, Diagnosis, CAGR, Patient, Angiography, SAN, Application, Glaucoma, Diabetic retinopathy, USD, Disease, Prevalence, Medical imaging, Coal, Technology

North America held the largest share in the optical coherence tomography market and is expected to maintain its dominance during the forecast period.

Key Points: 
  • North America held the largest share in the optical coherence tomography market and is expected to maintain its dominance during the forecast period.
  • Read 190-page market research report, " Optical Coherence Tomography Market Size, Share & Trends Analysis Report By Technology (Time Domain OCT, Frequency Domain OCT, Spatially Encoded Frequency Domain OCT), By Type, By Application, By Region, And Segment Forecasts, 2022 - 2030 ", published by Grand View Research.
  • These initiatives by market players can be positive for the optical coherence tomography market in the upcoming year.
  • Grand View Research has segmented the global optical coherence tomography market on the basis of technology, type, application, and region:
    Technology Outlook (Revenue in USD Million, 2017 - 2030)
    Type Outlook (Revenue in USD Million, 2017 - 2030)

Quantum-Si Reports Fourth Quarter and Fiscal Year 2021 Financial Results

Retrieved on: 
Monday, February 28, 2022
Health, Genetics, General Health, Research, Science, Biotechnology, Nasdaq, Board of directors, Proteomics, Investor, Partnership, ESPCI, Board, Growth, Risk, SEC, Interim, Investment, NASDAQ Biotechnology Index, Research, COVID-19, Adjustment, Company, Yale University, CA, Disease, Time domain, Interest, NBI, Review, Humanitarian use licenses, Adoption, Net, Index, Forecasting, BioRxiv, DNA, Leadership, PEI, Coronavirus Scientific Advisory Board (Turkey), Drug discovery, Marketing, Technology, Mission statement, Private Securities Litigation Reform Act, GAAP, EBITDA, Fine chemical, Management, Medical imaging, Airline, Bank, Pharmaceutical industry, Video game, Ridesharing company, Risk management

Research and development expenses were $14.4 million in the fourth quarter of 2021, compared to $6.4 million in the fourth quarter of 2020.

Key Points: 
  • Research and development expenses were $14.4 million in the fourth quarter of 2021, compared to $6.4 million in the fourth quarter of 2020.
  • Selling, general and administrative expenses were $13.4 million in the fourth quarter of 2021, compared to $3.2 million in the fourth quarter of 2020.
  • Adjusted EBITDA was negative $20.4 million in the fourth quarter of 2021, compared with negative $9.0 million in the fourth quarter of 2020.
  • Quantum-Si will host a conference call to discuss its fourth quarter and fiscal year 2021 financial results on Monday, February 28, 2022, at 4:30 PM Eastern Time.

Quantum-Si Provides Business Updates at the 40th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 10, 2022
Semiconductor, Health, Technology, Research, Science, Pharmaceutical, Biotechnology, U.S. Securities and Exchange Commission, Webcast, Technology, Conference, Manuscript, Nasdaq, COVID-19, Time domain, Partnership, BioRxiv, Growth, DNA, Proteomics, Marketing, Private Securities Litigation Reform Act, Company, Event, Drug discovery, Medical imaging, Management, Risk management

Jan. 10, 2022-- Quantum-Si Incorporated (Nasdaq: QSI) (Quantum-Si, or the Company), a life sciences tools company commercializing a single molecule protein sequencing platform, today announced that management will discuss the following business updates at the 40th Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • Jan. 10, 2022-- Quantum-Si Incorporated (Nasdaq: QSI) (Quantum-Si, or the Company), a life sciences tools company commercializing a single molecule protein sequencing platform, today announced that management will discuss the following business updates at the 40th Annual J.P. Morgan Healthcare Conference.
  • We look forward to discussing our progress and building upon our strong momentum as we continue our commercialization path in 2022.
  • To access the live webcast of Quantum-Sis virtual presentation at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 4:30 pm ET, please use the webcast link available in the Events & Presentations section of the Quantum-Si investor website.
  • A replay of the webcast will be available for a limited period following the conference.

Fission 3.0 Commences Geophysics on Flagship Property PLN

Retrieved on: 
Wednesday, December 22, 2021
Cloud, FUU, PLN, Fission Uranium Corp., Zinc, News, CORP, National instrument, Radioactive decay, Fission, Athabasca Basin, Time domain, Arrow, Nickel, Tropical cyclone, Feasibility study, TDEM, NexGen, Company, PLS, EM, Uranium, Boron, Copper, Triple, Lithium, Printed circuit board

Located in the same area as where Fission Uranium Corp and NexGen Energy are advancing their world-class, large, high-grade uranium deposits PLN is amongst the highest ranked projects in Fission 3's extensive portfolio.

Key Points: 
  • Located in the same area as where Fission Uranium Corp and NexGen Energy are advancing their world-class, large, high-grade uranium deposits PLN is amongst the highest ranked projects in Fission 3's extensive portfolio.
  • Previous drill programs at PLN have identified basement hosted uranium mineralization supported by the presence of alteration, pathfinder structural disturbance supporting large-scale potential of the area.
  • Ground Geophysics has commenced at Broach Lake to refine the targets for the upcoming drilling in the new year.
  • Several of Fission 3.0's projects are near large uranium discoveries, including Arrow, Triple R and Hurricane deposits.